Renocal Plus 435 mg+ 235 mg

Renocal Plus 435 mg+ 235 mg | INDICATIONS AND USES

This preparation tablet is indicated in the treatment of hyperphosphatemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis). This preparation tablet is indicated in adults.

Renocal Plus 435 mg+ 235 mg | PHARMACOLOGY

As calcium acetate and magnesium carbonate are phosphate-binding compounds, they lead together with the phosphate contained in food to the formation of low solubility calcium and magnesium phosphate-salts in the gut, which then will be excreted with the faeces. Calcium acetate reaches its maximal phosphate-binding capacity at a pH of 6-8. Therefore, this tablet is also suitable for phosphate binding in patients with hypo- or anacidity of the stomach.

Renocal Plus 435 mg+ 235 mg | DOSAGE & ADMINISTRATION

Adults: 3 to 10 film-coated tablets per day, depending on the serum phosphate level. The daily dose should be subdivided according to the number of meals per the day (usually 3 a day). The recommended starting dose is 3 tablets daily. If necessary, the dosage may be raised to maximally 12 film-coated tablets per day.Pediatric population: The safety and efficacy of this tablet in children and adolescence have not been established. Therefore, the administration of this tablet is not recommended in children and adolescents below 18 years of age.Method of administration: To achieve the maximum phosphate binding effect, this tablet must be taken together with the meal and should not be crushed or chewed. For easy swallowing, the tablets should be taken together with some liquid. In case the tablets are too large to be swallowed by the patient, the tablets should be broken along the score line immediately before swallowing in order to avoid the development of taste of acetic acid. Because the rate and/or extent of absorption of other defined medicinal products may vary when used concomitantly with this tablet, none of the oral medicinal products should be taken within the period 2 hours before and 3 hours after administration of this tablet. This can be applied long-term.

Renocal Plus 435 mg+ 235 mg | DRUG INTERACTIONS

To avoid any possible drug interaction between this tablet and susceptible oral medication when taken concomitantly should be taken within the period 2 hours before and 3 hours after administration of this tablet. This tablet affects the absorption of tetracyclines, doxycycline, norfloxacin, some cephalosporins like cefpodoxime, cefuroxime, and some quinolones (gyrase inhibitors) like ciprofloxacin), biphosphonates, fluorides, ketokonazole, estramustin-preparation, anticholinergics, iron supplements, digoxin, nitrofurantoin, levothyroxine. Vitamin D and derivatives, thiazide diuretics, oestrogens may affect the absorption of calcium. The sensitivity for glycosides and therefore the risk for arrhythmia is increased by elevated serumcalcium levels. The administration of adrenalin in patients with increased serum Calcium levels may lead to severe arrhythmia. The effect of Calcium antagonists may be reduced.

Renocal Plus 435 mg+ 235 mg | SIDE EFFECTS

Gastrointestinal disorders: Common: Soft stools, gastrointestinal irritation like nausea, anorexia, sensation of fullness, belching and constipation, diarrhoea.Metabolism and nutrition disorders: Common: Hypercalcaemia either asymptomatic or symptomatic, asymptomatic hypermagnesaemia. Uncommon: Moderate to severe symptomatic hypercalcaemia, symptomatic hypermagnesaemia. Very rare: Hyperkalaemia, magnesium-induced osteal mineralisation disturbances.

Renocal Plus 435 mg+ 235 mg | USE DURING PREGNANCY AND LACTATION

Pregnancy: There are no or limited amount of data from the use of this tablet in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. This tablet should not be used during pregnancy unless the clinical condition of the woman requires treatment with calcium acetate and magnesium carbonate. Lactation: This tablet is excreted in human milk to such an extent that effects on the breastfed newborns/infants are likely. Breastfeeding is not recommended during treatment with this tablet.

Renocal Plus 435 mg+ 235 mg | PRECAUTIONS & WARNINGS

This tablet should only be administered with caution (only with continuous monitoring of serum calcium, magnesium and phosphate) in case of severe hyperphosphataemia with a calcium-phosphate-product of more than 5.3 mmol/L if

refractory to therapy
refractory hyperkalaemia,
clinical relevant bradycardia or AV-block ll° with bradycardia.

Continuous monitoring of serum phosphate, serum magnesium, serum calcium and the calcium-phosphate-product should be performed, especially in case of simultaneous intake of vitamin D preparations and thiazide diuretics. High doses and long-term administration of this tablet may result in hypermagnesaemia. Hypermagnesaemia is mostly asymptomatic, but in some cases systemic effects may be seen. Caution should be taken while taking antacids and digitalis glycosides. If patients with a chronic renal insufficiency receive this tablet they may develop hypercalcaemic episodes, especially in combination with the administration of metabolites of vitamin D. Attention must be paid to the progression or the appearance of vascular and soft tissue calcifications. The risk decreases by lowering the calcium-phosphate-product to<4.5 mmol/L. Increased intake of calcium salts may result in the precipitation of fatty acids and bile acid as calcium soap. This may lead to constipation. In case of diarrhoea the dosage of this tablet should be reduced.

Renocal Plus 435 mg+ 235 mg | THERAPEUTIC CLASS

Specific mineral preparations

Renocal Plus 435 mg+ 235 mg | STORAGE CONDITIONS

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.